METTL16 promotes PD-L1 expression and mediates immunosuppression in B-cell lymphomas via m6A methylation.
OBJECTIVES Immune Checkpoint Inhibitors (ICIs) have changed cancer treatment. Altered expression of methyltransferase-like 16 (METTL16), one of the initial m6A "writers", is associated with malignant progression. METTL16 is a methyltransferase that may influence the treatment response of B-cell lymphoma (BCL). METHOD...